Dandu Biosciences develops biosimilar products using a proprietary peptide platform that achieves high yields and lowers production costs. Their lead product, Liraglutide, targets diabetes and obesity by enhancing insulin release and reducing gastric emptying, thereby minimizing the need for multiple insulin injections.
Funding
Funding not disclosed
Founders
Product
Problem
The management of diabetes and obesity often requires frequent insulin injections, which can be burdensome and inconvenient for patients. Existing treatments may not effectively control glycemic excursions or promote weight management, leading to suboptimal health outcomes.
Solution
Dandu Biosciences is developing biosimilar products, including Liraglutide, using a proprietary peptide platform designed for high yields and reduced production costs. Liraglutide, a semi-synthetic peptide, mimics natural GLP-1, augmenting insulin release in a glucose-dependent manner and reducing glucagon secretion. This dual action helps manage blood glucose levels and promotes weight loss by reducing gastric emptying and maximizing nutrient assimilation. Dandu Bio is developing Liraglutide in an auto-injector format to support both diabetic and obese patients, potentially reducing their reliance on multiple daily insulin injections.
Target Audience
The primary target audience includes individuals with diabetes and obesity who require effective glycemic control and weight management solutions.
Features
- Proprietary peptide platform for high-yield, low-cost production of biosimilars
- Liraglutide biosimilar that functions similarly to natural GLP-1
- Glucose-dependent insulin release stimulation
- Reduction of glucagon secretion
- Reduction of gastric emptying to maximize nutrient assimilation
- Auto-injector format for convenient self-administration